On Friday, Omnicare, Inc. (NYSE:OCR)’s shares inclined 0.26% to $94.85.
RxCrossroads, a Division of Omnicare, Inc. (OCR) Specialty Care Group (SCG), continues growing as the company looks to fill nearly 100 positions for its Louisville, Kentucky offices by the end of June 2015.
Omnicare SCG was formed in 2010 by combining the acquisition of RxCrossroads from 2005 and Advanced Care Scripts from 2008 into one clearly defined segment and strategy vision. Omnicare SCG provides customized end-to-end services starting with the biopharmaceutical manufacturer and ongoing through to the patient. The company develops innovative programs that integrate access, affordability and adherence for specialty drugs with services that comprise brand support, third party logistics, program pharmacy and specialty pharmacy.
Since 2013, employee growth at RxCrossroads has raised by 37% and plans for additional positions continue as a new office on Eastpoint Parkway in Louisville opened in November of 2014. There are presently three offices and two warehouses that RxCrossroads operates from in the Louisville area.
Omnicare, Inc. operates as a healthcare services company that specializes in the administration of pharmaceutical care in the United States. The company’s Long-Term Care Group segment offers pharmaceuticals, and related pharmacy and ancillary services to long-term care facilities; and chronic care facilities and other settings.
International Game Technology Ordinary Shares (NYSE: IGT)’s shares dropped -0.99% to $14.06.
International Game Technology Ordinary Shares (IGT) declared that its Annual General Meeting of Shareholders will be held in London, U.K. on July 28, 2015. In accordance with the U.K. Companies Act, IGT’s Board of Directors has established July 24, 2015 as the record date for determining the shareholders entitled to vote at the Meeting.
International Game Technology PLC operates and provides a range of services and technology products across lotteries, machine gaming, sports betting, and interactive gaming markets in North America, Asia, and Europe. It provides online lottery transaction processing systems; a suite of lottery-enabled point-of-sale terminals; supplies instant ticket games; and provides printing services, instant ticket marketing plans, graphic design, and programming, production, packaging, and shipping and delivery services.
At the end of Friday’s trade, Arrow Electronics, Inc. (NYSE:ARW)‘s shares dipped -0.54% to $58.82.
Arrow Electronics, Inc. (ARW) declared that four of its up-and-coming women leaders were named to The Channel Company’s CRN® Women of the Channel list for 2015: Lisa Braun, Stephanie Dura, Karey Keiley and Linda Peterson.
The annual Women of the Channel list honors outstanding female executives across the IT channel ecosystem for their success and the far-reaching impact they are having on the technology industry going forward. This year’s Women of the Channel were selected by the editors of CRN based on their accomplishments and influence.
Braun is a planned account executive for Arrow and is based in Cleveland, Ohio. She has been pivotal in differentiating Arrow’s value in the marketplace and communicating that value to the company’s customers.
Dura is a finance director based in Denver, Colo. She supported the launch of Arrow’s successful ECS Partner Account Administration program, and she also focuses on automation and operational excellence.
Peterson is a senior manager of inside sales and is based in Minneapolis, Minn. She has worked to better understand the needs of Arrow’s vendors and partners, and to enable them to implement converged infrastructure offerings.
Arrow Electronics, Inc. provides products, services, and solutions to industrial and commercial users of electronic components and enterprise computing solutions worldwide. The company operates in two segments, Global Components and Global Enterprise Computing Solutions.
Hemispherx BioPharma, Inc (NYSEMKT:HEB), ended its Friday’s trading session with –0.09% loss, and closed at $0.229.
Hemispherx BioPharma, Inc (HEB) declares that the European Medicines Agency (EMA) has published on May 22, 2015 both its Public Opinion Summary (http://www.ema.europa.eu/docs/en_GB/document_library/Orphan_designation/2015/05/WC500187066.pdf) and its record designation (http://ec.europa.eu/health/documents/community-register/html/o1480.htm) approving the Orphan Medicinal Product Designation for Ampligen, also known as rintatolimod, an experimental therapeutic, to treat Ebola Virus Disease (EVD).
The EMA opinion states that the experimental drug, “… is made up of two synthetic molecules of RNA (a type of genetic material), which are attached together. It is thought that the medicine works in two ways; first, by stimulating cells involved in the body’s innate immune system (via receptors known as TLR 3), and secondly, by stimulating the production of interferons, a group of signaling proteins involved in protecting the body against viruses.”
Thomas K. Equels, Executive Vice Chairman, states, “The European Medicines Agency rationale for designation of our experimental drug Ampligen(R)/Rintatolimod as an orphan drug is assistful to understanding our path forward seeking commercial approval of Ampligen(R) (rintatolimod) as a prophylactic and early onset therapeutic for Ebola and other lethal viral diseases. Accordingly, the Public Summary Opinion and the designation have both been posted on our website to facilitate public review of the actual documents.” The EMA orphan drug designation Public Opinion Summary will be posted on the Company website www.hemispherx.net.
Hemispherx Biopharma, Inc., a specialty pharmaceutical company, engages in the clinical development of new drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders in the United States.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
